Ozempic was first approved to treat diabetes in Canada seven years ago. Now the largest study of its kind suggests it and ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published online Jan. 21 in JAMA Network ...

BROWNSVILLE — It was an unusually cold Saturday morning in the Rio Grande Valley but that didn't stop hundreds of people from forming a line that wound throughout the south side of the Brownsville ...

The state health plan currently has a $507 million deficit. Pharmacy benefit managers, the intermediaries in the drug supply chain, are supposed to use their bargaining power to negotiate lower drug ...

According to the Centers for Disease Control and Prevention (CDC), sugary drinks are the primary source of added sugars in the American diet, contributing to a host of health issues […] ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

A retrospective study demonstrated slightly elevated baseline fasting plasma glucose levels to be a robust marker of incident diabetes risk, even when those levels fell within the normal range.

Adults with overweight or obesity and type 2 diabetes who are given the sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin alongside moderate calorie restriction achieve much higher ...

New research suggests that factors like age, sex, body fat and the amount of sugar in your blood play a significant role in the progression from pre-diabetes to a type 2 diabetes diagnosis.

Overweight scores continue from 25-30. And over 30 is obese. Quetelet merely used this early calculation as a descriptor. He did not make any medical proclamations. The Quetelet Index became ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.